A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor.
Leiserson MDM, Syrgkanis V, Gilson A, Dudik M, Gillett S, Chayes J, Borgs C, Bajorin DF, Rosenberg JE, Funt S, Snyder A, Mackey L.
Leiserson MDM, et al. Among authors: borgs c.
PLoS One. 2018 Dec 31;13(12):e0208422. doi: 10.1371/journal.pone.0208422. eCollection 2018.
PLoS One. 2018.
PMID: 30596661
Free PMC article.